{
    "clinical_study": {
        "@rank": "75605", 
        "arm_group": [
            {
                "arm_group_label": "NNC0195-0092", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Norditropin\u00ae", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe and Asia. The aim of the trial is to investigate safety,\n      tolerability, pharmacokinetics (the exposure of the trial drug in the body) and\n      pharmacodynamics (the effect of the investigated drug on the body) of a single dose of\n      long-acting growth hormone (NNC0195-0092) compared to daily dosing of Norditropin\u00ae SimpleXx\u00ae\n      (somatropin) in children with growth hormone deficiency."
        }, 
        "brief_title": "A Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth Hormone Compared to Daily Dosing of Norditropin\u00ae SimpleXx\u00ae in Children With Growth Hormone Deficiency", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Growth Hormone Disorder", 
            "Growth Hormone Deficiency in Children"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Dwarfism, Pituitary", 
                "Endocrine System Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Confirmed diagnosis of GHD (growth hormone deficiency) as defined by two different GH\n             (growth hormone) stimulation tests, peak GH level below or equal to 7.0 ng/ml. For\n             children with three or more pituitary hormone deficiencies only one GH stimulation\n             test will be needed. If in accordance with country specific practice, growth hormone\n             deficiency can be defined by only one GH stimulation test, peak GH level below or\n             equal to 7.0 ng/ml.\n\n          -  Pre-pubertal children at screening. Boys: Tanner stage 1 and age above or equal to 6\n             years and below 13 years. Girls: Tanner stage 1 and age above or equal to 6 years and\n             below 12 years\n\n          -  Body weight above or equal to 16.0 kg and below or equal to 50.0 kg\n\n          -  Stable GH replacement treatment for at least 3 months\n\n        Exclusion Criteria:\n\n          -  History or presence of malignancy\n\n          -  Overt diabetes mellitus (fasting blood glucose above or equal to 7.0 mmol/l)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "13 Years", 
            "minimum_age": "6 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01973244", 
            "org_study_id": "NN8640-4042", 
            "secondary_id": [
                "2013-000013-20", 
                "U1111-1138-2206"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "NNC0195-0092", 
                "description": "A single dose administered subcutaneously (s.c., under the skin) of 4 different doses of NNC0195-0092 in an escalating order.\nEach subject will be allocated to one dose level only. After completion of each dose cohort, a safety evaluation will be conducted prior to dose escalation.", 
                "intervention_name": "NNC0195-0092", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Norditropin\u00ae", 
                "description": "Administered subcutaneously (s.c., under the skin) once daily for 7 days. The daily dose is 0.03 mg/kg/day.", 
                "intervention_name": "somatropin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Hormones"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "February 25, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Wien", 
                        "country": "Austria", 
                        "zip": "A 1090"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brussels", 
                        "country": "Belgium", 
                        "zip": "1090"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75015"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Petah Tikva", 
                        "country": "Israel", 
                        "zip": "49202"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Skopje", 
                        "country": "Macedonia, The Former Yugoslav Republic of", 
                        "zip": "1000"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bergen", 
                        "country": "Norway", 
                        "zip": "5021"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ljubljana", 
                        "country": "Slovenia", 
                        "zip": "1525"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vitoria", 
                        "country": "Spain", 
                        "zip": "01009"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stockholm", 
                        "country": "Sweden", 
                        "zip": "141 86"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Basel", 
                        "country": "Switzerland", 
                        "zip": "4031"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Austria", 
                "Belgium", 
                "France", 
                "Israel", 
                "Macedonia, The Former Yugoslav Republic of", 
                "Norway", 
                "Slovenia", 
                "Spain", 
                "Sweden", 
                "Switzerland"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomised, Open-labelled, Active-controlled, Multinational, Dose-escalation Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth Hormone (NNC0195-0092) Compared to Daily Dosing of Norditropin\u00ae SimpleXx\u00ae in Children With Growth Hormone Deficiency", 
        "overall_contact": {
            "email": "clinicaltrials@novonordisk.com", 
            "last_name": "Novo Nordisk"
        }, 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Austria: Agency for Health and Food Safety", 
                "Belgium: Federal Agency for Medicines and Health Products, FAMHP", 
                "France: Ministry of Health", 
                "Israel: Israeli Health Ministry Pharmaceutical Administration", 
                "Macedonia, The Former Yugoslav Republic of: Ministry of Health", 
                "Norway: Norwegian Medicines Agency", 
                "Slovenia: Agency for Medicinal Products - Ministry of Health", 
                "Spain: Spanish Agency of Medicines", 
                "Sweden: Medical Products Agency", 
                "Switzerland: Federal Office of Public Health"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Incidence of adverse events (AEs)", 
            "safety_issue": "No", 
            "time_frame": "From first administration of trial product and up until day 35 (final visit)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01973244"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "The area under the insulin-like growth factor I (IGF-I) concentration-time curve", 
            "safety_issue": "No", 
            "time_frame": "From 0 to 168 hours after dosing"
        }, 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}